Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-06-15T21:56:53.236Z Has data issue: false hasContentIssue false

P0327 - Ethane as a biomarker of schizophrenia

Published online by Cambridge University Press:  16 April 2020

B.K. Puri
Affiliation:
MRI Unit, Imaging Sciences Department, MRC CSC, Imperial College London, Hammersmith Hospital, London, UK
B.M. Ross
Affiliation:
Division of Medical Sciences, Northern Ontario School of Medicine, Lakehead University, Ontario, Canada
I.H. Treasaden
Affiliation:
Three Bridges Medium Secure Unit, West London Mental Health NHS Trust, Imperial College London, Southall, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

This study directly assessed whether there was a change in the level of exhaled ethane, which provides a non-invasive, quantitative, direct measure of n-3 lipid peroxidation, in the breath of patients with schizophrenia.

Methods:

Samples of alveolar air were obtained from 20 subjects with schizophrenia and 23 age- and sex-matched healthy control subjects. The air samples were analyzed for ethane using mass spectrometry.

Results:

The mean level of ethane in the schizophrenia sample (5.15 (S.E. 0.56) ppb) was significantly higher than that of the healthy controls (2.63 (S.E. 0.31) ppb; p < 0.0005). A further sub-analysis showed that nicotine dependence was unlikely to be the cause of this difference.

Conclusion:

These results suggest that the measurement of exhaled ethane levels may offer a non-invasive direct marker of increased n-3 lipid peroxidation in schizophrenia.

Type
Poster Session I: Biological Markers
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.